The oncogenic ability of this mutation is also supported by a study in which a bladder carcinoma cell line expressing FGFR3b–Y375C lost its transforming ability upon treatment with an FGFR kinase inhibitor and/or FGFR3 shRNA (27). The gene discussed is FGFR3; the disease is urinary bladder carcinoma.